"GLP-3" Does Not Exist as a Validated Receptor Target
A research assistant tasked with sourcing a "GLP-3 agonist" for a bench comparison will hit a wall almost immediately. A search of PubMed for "GLP-3 receptor" returns no cloned gene, no crystal structure, no cAMP assay data, and no entry in the IUPHAR/BPS Guide to Pharmacology. This is not a gap in indexing. Glucagon-like peptide-1 (GLP-1) is one of several proglucagon-derived peptides, alongside glucagon and oxyntomodulin, and its receptor (GLP1R, chromosome 6p21.2) has been cloned, sequenced, and structurally resolved by cryo-EM for more than two decades. No parallel "GLP-3" gene or protein has been characterized in the peer-reviewed literature.
The term surfaces almost exclusively in commercial contexts — research-peptide marketing copy, brand names, and forum shorthand for newer multi-receptor agonists such as retatrutide. That is a naming convention, not a pharmacological classification. Confusing a marketing label with a validated receptor target has real consequences: a lab or clinician evaluating "selectivity" for a target that has never been sequenced cannot compare binding affinity, potency, or off-target liability against anything, because there is no reference ligand, no radioligand-binding assay, and no accepted nomenclature to anchor the comparison.
What follows is a comparative look at the receptor family that actually underlies this class of compounds — GLP-1R, the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR) — using the binding affinity and potency data that has been published for semaglutide, tirzepatide, and retatrutide. That is the selectivity paradigm that is measurable, and it is the one that determines tolerability and efficacy in the clinic.
The Class B GPCR Family Behind the Confusion
GLP1R, GIPR, and GCGR belong to class B1 of the G-protein-coupled receptor superfamily, sharing roughly 44–52% amino acid sequence identity across the transmembrane core. All three are secretin-family receptors built on a two-domain architecture: a large extracellular domain (ECD) that captures the C-terminal portion of the peptide ligand, and a seven-transmembrane (7TM) bundle that engages the ligand's N-terminus to trigger conformational activation and Gs-coupled adenylate cyclase signaling.
Cryo-EM structures of GLP-1R bound to peptide and small-molecule agonists (Zhang et al., Nature, 2017) established the "two-domain binding" mechanism that now guides rational design of dual and triple agonists. Because GIPR and GCGR share this same architecture, a peptide engineered to engage GLP-1R's ECD-binding groove can often be modified at specific residues to gain or lose affinity at GIPR or GCGR without a full redesign — this is the actual structural basis of the "multi-receptor selectivity paradigm" that compound developers are working within.
Sequence homology, however, does not equal interchangeable pharmacology. GLP1R, GIPR, and GCGR each couple to distinct downstream signaling magnitudes and kinetics, and each is expressed in a different tissue distribution — GLP1R predominantly in pancreatic beta cells, gastric vagal afferents, and hypothalamic nuclei; GIPR broadly in adipose tissue and beta cells; GCGR primarily in hepatocytes. Selectivity between these three receptors, not a fictitious fourth target, is what determines a compound's metabolic profile.
GLP-1 Receptor Potency: Semaglutide as the Reference Ligand
Native GLP-1(7-36) amide activates GLP1R with sub-nanomolar potency but has a circulating half-life under two minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). Semaglutide (Ozempic/Wegovy) was engineered specifically to preserve GLP1R affinity while extending half-life to approximately one week, achieved through two modifications: substitution of alanine at position 8 with 2-aminoisobutyric acid (Aib8) to block DPP-4 cleavage, and attachment of a C18 fatty diacid via a glutamic acid/gamma-glutamic acid linker at lysine-26 that promotes reversible albumin binding (Lau et al., J Med Chem, 2015, PMID 26308362).
In cAMP accumulation assays, semaglutide's functional potency at human GLP1R is in the low-to-sub-nanomolar EC50 range, broadly comparable to native GLP-1 and modestly higher than liraglutide, which carries a shorter C16 fatty-acid chain and a half-life closer to 13 hours. The albumin-binding strategy does not change intrinsic receptor affinity so much as it changes pharmacokinetic exposure — the drug is presented to GLP1R-expressing tissue continuously rather than in a pulsatile pattern, which is one proposed mechanism for its improved glycemic and weight-loss effect sizes relative to shorter-acting GLP-1 receptor agonists such as exenatide.
Researchers evaluating the original semaglutide discovery data should note that potency alone did not distinguish semaglutide from earlier analogues; the pharmacokinetic engineering did. That distinction — potency versus exposure — is frequently collapsed in secondary marketing material and is worth separating explicitly in any protocol comparing GLP-1R ligands.
Dual Agonism: Tirzepatide's GIPR/GLP-1R Selectivity Profile
Tirzepatide (Mounjaro/Zepbound) is a 39-amino-acid peptide engineered as a dual GIP/GLP-1 receptor co-agonist, and its published receptor pharmacology is the clearest published example of an intentionally asymmetric selectivity profile. In vitro characterization by Willard and colleagues (JCI Insight, 2020, PMID 32302947) found that tirzepatide's cAMP potency at human GIPR is comparable to, or in some assay systems modestly greater than, native GIP, while its potency at human GLP1R is roughly five-fold lower than native GLP-1.
That asymmetry is deliberate rather than a manufacturing limitation. The same study reported that tirzepatide produces less beta-arrestin recruitment and less GLP1R internalization than native GLP-1 at matched receptor occupancy — a biased-agonism profile that traffics the receptor away from desensitization pathways. The pharmacologic hypothesis is that reduced GLP1R-mediated internalization, combined with balanced or GIPR-forward signaling, contributes to the drug's discontinuation-adjusted weight-loss effect size in the SURMOUNT program (ClinicalTrials.gov NCT04184622), where SURMOUNT-1 reported mean weight reductions of up to 20.9% at the 15 mg dose over 72 weeks versus 3.1% for placebo (n=2,539).
What is still unresolved in the literature is the precise quantitative contribution of GIPR co-agonism to the tolerability profile independent of the GLP1R bias effect — animal models show conflicting signals on whether GIPR activation attenuates or is neutral to GLP1R-driven nausea, and this remains an open question for ongoing mechanistic work rather than a settled finding.
Triple Agonism: Retatrutide and the Expanding Selectivity Paradigm
Retatrutide extends the same design logic one receptor further, functioning as a triple agonist at GIPR, GLP1R, and GCGR. Preclinical characterization (Coskun et al., Cell Metabolism, 2022, PMID 35914529) reported balanced, high potency across all three receptors in cell-based cAMP assays, with GCGR engagement — absent from semaglutide and tirzepatide — theorized to increase energy expenditure and hepatic lipid oxidation on top of the appetite-suppressing and insulinotropic effects shared with the other two receptors.
The phase 2 trial (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov NCT04867785, n=338, 48 weeks) reported a mean weight reduction of 24.2% at the 12 mg dose versus 2.1% with placebo — the largest effect size reported to date for an incretin-class agent in a randomized trial of this duration. Discontinuation due to adverse events, predominantly gastrointestinal, occurred in a minority of participants across active-dose arms, and dose-escalation schedule appeared to modulate tolerability, consistent with the class-wide pattern seen with semaglutide and tirzepatide.
What the phase 2 data does not yet establish is durability beyond 48 weeks, comparative cardiovascular outcome data, or how the added GCGR agonism interacts with hepatic glucose output in populations with impaired glycemic control — all of which are relevant open questions for the phase 3 program still underway. This is Phase 2 evidence: promising in effect size, but not yet the tier of evidence that supports broad clinical extrapolation.
Why Receptor Bias and Internalization Kinetics Matter More Than Kd Alone
A binding constant (Kd) describes how tightly a ligand occupies a receptor at equilibrium; it says nothing about what happens after the receptor is occupied. Functional selectivity — also called biased agonism — describes the downstream signaling consequences of that occupancy, and two ligands with similar Kd values at the same receptor can produce meaningfully different physiological outcomes depending on which intracellular pathway they preferentially activate.
For GLP1R specifically, activation triggers at least two parallel processes: Gs-protein coupling that drives cAMP-dependent insulin secretion, and beta-arrestin recruitment that drives receptor internalization and eventual desensitization. A ligand biased toward the Gs pathway and away from arrestin recruitment can, in principle, sustain a therapeutic signal longer at a given plasma concentration than a ligand of equal raw affinity that is rapidly internalized and degraded.
This is the mechanistic detail that a simple affinity table cannot capture, and it is why comparative pharmacology papers increasingly report internalization half-times and arrestin-recruitment EC50 values alongside classical Kd and cAMP EC50 figures. For anyone building a research protocol around receptor selectivity claims, the practical takeaway is to request or locate the bias-signaling data, not just the headline binding number, before drawing conclusions about why two structurally similar compounds might behave differently in a trial population.
Comparative Potency Snapshot Across Published Ligands
The figures below are drawn from the cell-based functional assays cited above and are intended as an orientation, not a substitute for the primary papers, since assay conditions (cell line, receptor expression level, assay readout) affect absolute EC50 values even when relative rank-order is preserved across studies.
- Native GLP-1(7-36): sub-nanomolar EC50 at GLP1R in cAMP assays; circulating half-life under 2 minutes due to DPP-4 cleavage.
- Semaglutide: low-to-sub-nanomolar EC50 at GLP1R, comparable to native GLP-1; ~1 week half-life via albumin binding and DPP-4 resistance (Aib8 substitution).
- Liraglutide: nanomolar-range EC50 at GLP1R; ~13-hour half-life via C16 fatty-acid albumin binding.
- Tirzepatide: GIPR potency comparable to or exceeding native GIP; GLP1R potency approximately 5-fold lower than native GLP-1, with reduced arrestin recruitment/internalization at GLP1R (Willard et al., 2020).
- Retatrutide: balanced sub-nanomolar-to-nanomolar potency reported across GIPR, GLP1R, and GCGR in preclinical cell assays (Coskun et al., 2022); the only compound in this comparison with meaningful GCGR engagement.
The pattern across all three engineered molecules is not indiscriminate potency maximization — it is targeted rebalancing of relative receptor engagement, which is the actual, publishable version of the "selectivity paradigm" this class of research is built around.
Clinical Implications of Selectivity Differences for Tolerability and Efficacy
Gastrointestinal adverse events — nausea, vomiting, diarrhea — remain the dominant tolerability signal across every GLP1R-active compound reported to date, and their incidence tracks with both dose and titration speed rather than with a single receptor-affinity number. In SURMOUNT-1, GI adverse events occurred in over 60% of participants across active tirzepatide arms, mostly mild-to-moderate and concentrated during dose escalation; in the retatrutide phase 2 trial, GI adverse events showed a similar dose-dependent pattern, with discontinuation rates rising at the highest studied dose.
The clinical decision-making relevance of the receptor-selectivity data is therefore practical rather than academic: a compound with GIPR co-agonism and reduced GLP1R internalization (tirzepatide) is not automatically better tolerated than a GLP1R-selective agent (semaglutide) at a matched degree of weight loss — head-to-head data (SURMOUNT-2 vs. STEP program comparisons, indirect) suggest broadly similar GI adverse-event rates when doses are titrated on comparable schedules, even though the underlying receptor engagement differs substantially.
What the affinity and potency data support is a mechanistic explanation for observed effect sizes, not a guarantee of individual tolerability. Monitoring practice in trials for this class has converged on similar elements regardless of receptor profile: baseline and periodic renal function given GI-fluid-loss risk, gallbladder symptom screening given elevated cholelithiasis signal across the class, and slow dose titration schedules — typically 4-week steps — that are themselves a bigger lever on tolerability than the specific receptor-binding profile of the molecule.
Where Marketing Nomenclature Diverges From Receptor Pharmacology
Research-peptide suppliers frequently use receptor-family names loosely, and "GLP-3" is one recurring example of a label applied to differentiate a product without a corresponding entry in receptor pharmacology databases. This matters beyond semantics: a buyer or research team relying on a supplier's stated receptor target, rather than independent mass spectrometry and a certificate of analysis (COA), has no way to confirm what compound is actually in the vial, let alone what receptor it engages.
This is a documented problem across the broader research-peptide supply chain, not specific to any one term. Peptide identity and purity in the unregulated research-use-only market can vary substantially between suppliers and even between lots from the same supplier, since these products are explicitly labeled "not for human use" and fall outside FDA manufacturing oversight that applies to approved pharmaceutical products.
For any protocol built around a stated receptor-selectivity claim, the verification chain should run in the opposite direction from the marketing copy: start from the peer-reviewed pharmacology paper describing the receptor and ligand in question, confirm the receptor's gene identity (GLP1R, GIPR, GCGR) against a reference database such as UniProt or the IUPHAR/BPS Guide to Pharmacology, and only then evaluate whether a given commercial product's claimed selectivity profile is consistent with anything published. A receptor name that does not resolve to a gene, a structure, or a binding assay in that chain is not a basis for a selectivity comparison.
What This Means for Ongoing Research — and the Next Step for Evaluating Selectivity Claims
The genuine frontier in this space is not a fourth incretin receptor but deeper characterization of bias signaling, tissue-specific receptor trafficking, and interspecies differences in receptor pharmacology that complicate translation from rodent and cell-line data to human outcomes. Structural biology groups continue to resolve additional GLP1R and GIPR conformational states, which is expected to refine understanding of why chemically similar analogues produce measurably different arrestin-recruitment profiles. Ongoing phase 3 work on retatrutide and next-generation triple and quadruple agonists (including amylin-incorporating designs) will generate the longer-duration safety and durability data that current phase 2 evidence cannot provide.
Any claim about a novel receptor target reaching the literature would need to clear the same bar every characterized incretin receptor has cleared: gene cloning, structural resolution, and reproducible binding/functional assay data published in a peer-reviewed journal — the same standard applied to GLP1R, GIPR, and GCGR above. Until that bar is met for any additional target, the most defensible framing for researchers, clinicians, and informed patients evaluating this compound class is to anchor comparisons to the three validated receptors and their published affinity and potency data, and to treat receptor-name claims that do not resolve to a peer-reviewed source as unverified marketing language rather than pharmacology.
The practical next step is a five-minute source check rather than a marketing comparison chart: pull the primary pharmacology paper for the compound in question, confirm the receptor names against GLP1R, GIPR, or GCGR in a reference database such as UniProt or the IUPHAR/BPS Guide to Pharmacology, and check whether the potency and bias-signaling data were generated in human receptor constructs or a rodent surrogate, since translation between species is not automatic. That single habit — tracing a selectivity claim back to a cloned gene and a published assay rather than a product label — is what separates a defensible research comparison from a repackaged marketing claim, whether the compound in question is semaglutide, tirzepatide, retatrutide, or any future entrant in this receptor family.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.